Comparison between dobutamine and levosimendan for management of postresuscitation myocardial dysfunction

Critical Care Medicine

Volumn 33, Issue 3, 2005, Pages 487-491

  Huang, Lei ^a   Weil, Max Harry ^a,b   Tang, Wanchun ^a,b   Sun, Shijie ^a,b   Wang, Jinglan ^a  

^a INSTITUTE OF CRITICAL CARE MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cardiopulmonary resuscitation; Inotrope; Myocardial dysfunction; Postresuscitation; Stunning

Indexed keywords

CALCIUM SENSITIZER; DILUENT; DOBUTAMINE; INOTROPIC AGENT; LEVOSIMENDAN; PLACEBO; SODIUM CHLORIDE;

ANIMAL MODEL; ARTICLE; ARTIFICIAL VENTILATION; BODY WEIGHT; CIRCULATION; COMPRESSION; CONTROLLED STUDY; DEFIBRILLATION; DRUG EFFECT; HEART ARREST; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE INJURY; HEART OUTPUT; HEART RIGHT ATRIUM; HEART VENTRICLE FIBRILLATION; MALE; NONHUMAN; PRIORITY JOURNAL; RESUSCITATION; SWINE;

ANALYSIS OF VARIANCE; ANIMALS; CARDIOMYOPATHIES; CARDIOPULMONARY RESUSCITATION; CARDIOTONIC AGENTS; DOBUTAMINE; HEART ARREST; HYDRAZONES; MALE; MYOCARDIAL STUNNING; PROSPECTIVE STUDIES; PYRIDAZINES; RANDOM ALLOCATION; SWINE;

EID: 14944348020     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000156241.55872.15     Document Type: Article

References (38)

1. Gazmuri RJ, Weil MH, Bisera J, et al: Myocardial dysfunction after successful resuscitation from cardiac arrest. Crit Care Med 1996; 24:992-1000
2. Braunwald E, Kloner RA: The stunned myocardium: Prolonged, postischemic ventricular dysfunction. Circulation 1982; 66: 1146-1149
3. Kern KB, Hilwig RW, Rhee KH, et al: Myocardial dysfunction following resuscitation from cardiac arrest: An example of global myocardial stunning. J Am Coll Cardiol 1996; 28:232-240
4. Tang W, Weil MH, Sun S, et al: Progressive myocardial dysfunction after cardiac resuscitation. Crit Care Med 1993; 21:1046-1050
5. Laurent I, Spaulding C, Monchi M, et al: Transient shock after successful resuscitation: Clinical evidence for post cardiac arrest myocardial stunning. J Am Coll Cardiol 2000; 35(Suppl A):399A
6. Laurent I, Monchi M, Chiche JD, et al: Reversible myocardial dysfunction in survivors of out-of hospital cardiac arrest. J Am Coll Cardiol 2002; 40:2110-2116
7. Tang W, Weil MH, Sun S, et al: Epinephrine increases the severity of postresuscitation myocardial dysfunction. Circulation 1995; 92:3089-3093
8. Yamaguchi H, Weil MH, Tang W, et al: Myocardial dysfunction after electrical defibrillation. Resuscitation 2002; 54:289-296
9. Tang W, Weil MH, Sun S, et al: Progressive myocardial dysfunction after cardiac resuscitation. Crit Care Med 1993; 21:1046-1050
10. Ditchey RV, Goto Y, Lindenfeld J: Myocardial oxygen requirements during experimental cardiopulmonary resuscitation. Cardiovasc Res 1992; 26:791-797
11. Michael JR, Guerci AD, Koehler RC, et al: Mechanisms by which epinephrine augments cerebral and myocardial perfusion during cardiopulmonary resuscitation in dogs. Circulation 1984; 69:822-835
12. Kern KB, Hilwig RW, Berg RA, et al: Postresuscitation left ventricular systolic and diastolic dysfunction: Treatment with dobutamine. Circulation 1997; 95:2610-2613
13. Vasquez A, Karl KB, Hilwig RW, et al: Optimal dosing of dobutamine for treating post-resuscitation left ventricular dysfunction. Resuscitation 2004; 61:199-207
14. Levijoki J, Pollesello P, Kaivola J, et al: Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: Structure-response and binding analysis with analogs of levosimendan. J Mol Cell Cardiol 2000; 32:479-491
15. Holubarsch C: New inotropic concepts: Rationale for and differences between calcium sensitizers and phosphodiesterase inhibitors. Cardiology 1007; 88(Suppl 2):12-20
16. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 1995; 77: 107-113
17. 2+ sensitizer, levosimendan, to recombinant human cardiac troponin C: A molecular modeling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem 1994; 269:28584-28590
18. Jamali IN, Kersten JR, Pagel PS, et al: Intracoronary levosimendan enhances contractile function of stunned myocardium. Anesth Analg 1997; 85:23-29
19. Kersten JR, Montgomery MW, Pagel PS, et al: Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg 2000; 90:5-11
20. Nijhawan N, Nicolosi AC, Montgomery MW, et al: Levosimendan enhances cardiac performance after cardiopulmonary bypass: A prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 1999; 34: 219-228
21. Institute of Laboratory Animal Resources: Guide for the Care and Use of Laboratory Animals (NIH publication 86-32). Bethesda, MD, National Institutes of Health, 1985
22. Klouche K, Weil MH, Sun S, et al: Evaluation of the stone heart after prolonged cardiac arrest. Chest 2002; 122:1006-1011
23. 2-selective vasopressor agent for cardiopulmonary resuscitation. Circulation 2003; 25:2716-2721
24. Folláth F, Hinkka S, Jäger D, et al: Dose-ranging and safety with intravenous levosimendan in low-output heart failure: Experience in three pilot studies and outline of the levosimendan infusion versus dobutamine (LIDO) trial. Am J Cardiol 1999; 83:21(I)-25(I)
25. Moiseyev VS, Poder P, Andrejevs N, et al: Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. Eur Heart J 2002; 23: 1422-1432
26. Pagel PS, McGough MF, Hettrick DA, et al: Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy. J Cardiovasc Pharmacol 1997; 29: 563-573
27. Sundberg S, Lilleberg J, Nieminen MS, et al: Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men. Am J Coll Cardiol 1995; 75:1061-1066
28. Slawsky MT, Colucci WS, Gottlieb SS, et al: Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure: Study investigators. Circulation 2000; 102:2222-2227
29. Weil MH, Michaels S, Puri VK, et al: The Stat laboratory: Facilitating blood gas and biochemical measurements for the critically ill and injured. Am J Clin Pathol 1981; 76: 34-42
30. du Toit E, Hofmann D, McCarthy J, et al: Effects of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligation and reperfusion in the vivo pig model. Heart 2001; 86:81-87
31. Nicklas JM, Monsur JC, Bleske BE: Effects of intravenous levosimendan on plasma neurohormone levels in patients with heart failure: Relation to hemodynamic response. Am J Cardiol 1999; 83:12(I)-15(I)
32. Lilleberg J, Sundberg S, Nieminen MS: Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction. J Cardiovasc Pharmacol 1995; 26(Suppl 1):63-69
33. Nieminen MS, Akkila H, Hasenfuss G, et al: Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000; 36:1903-1912
34. + channel in rat ventricular cell. J Pharmacol Exp Ther 1997; 283:375-383
35. Follath F, Cleland JG, Just H, et al: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomized double blind trial. Lancet 2002; 360:196-202
36. Nieminen MS: Levosimendan compared with dobutamine in low output patients. Minerva Anestesiol 2003; 69:258-263
37. Lehtonen LA: Levosimendan: A parenteral calcium-sensitizing drug with additional vasodilatory properties. Expert Opin Investig Drugs 2001; 10:955-970
38. Hasenfuss G, Pieske B, Castell M, et al: Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998; 98:2141-2147